230 related articles for article (PubMed ID: 28594478)
21. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Bergh M; Marais CA; Miller-Jansön H; Salie F; Stander MP
S Afr Med J; 2013 Feb; 103(4):241-5. PubMed ID: 23547700
[TBL] [Abstract][Full Text] [Related]
22. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
[TBL] [Abstract][Full Text] [Related]
23. Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.
von Schéele B; Fernandez M; Hogue SL; Kwong WJ
Ann Pharmacother; 2013 May; 47(5):671-85. PubMed ID: 23606551
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ
Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833
[TBL] [Abstract][Full Text] [Related]
25. Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.
Hesselbjerg LJ; Pedersen HS; Asmussen MB; Petersen KD
J Med Econ; 2013 Jul; 16(7):845-58. PubMed ID: 23621506
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
Langkilde LK; Bergholdt Asmussen M; Overgaard M
J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
[TBL] [Abstract][Full Text] [Related]
27. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Rudakova AV; Tatarskiĭ BA
Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
You JH; Tsui KK; Wong RS; Cheng G
PLoS One; 2012; 7(6):e39640. PubMed ID: 22745801
[TBL] [Abstract][Full Text] [Related]
29. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.
Pink J; Lane S; Pirmohamed M; Hughes DA
BMJ; 2011 Oct; 343():d6333. PubMed ID: 22042753
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
Singh SM; Micieli A; Wijeysundera HC
Circulation; 2013 Jun; 127(24):2414-23. PubMed ID: 23697908
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation.
Zhao YJ; Lin L; Zhou HJ; Tan KT; Chew AP; Foo CG; Oh CT; Lim BP; Lim WS
Int J Cardiol; 2016 Oct; 220():794-801. PubMed ID: 27400183
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.
Li X; Tse VC; Lau WC; Cheung BM; Lip GY; Wong IC; Chan EW
PLoS One; 2016; 11(6):e0157129. PubMed ID: 27362421
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
Lanitis T; Kongnakorn T; Jacobson L; De Geer A
Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.
Kamel H; Easton JD; Johnston SC; Kim AS
Neurology; 2012 Oct; 79(14):1428-34. PubMed ID: 22993279
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
Wouters H; Thijs V; Annemans L
J Med Econ; 2013; 16(3):407-14. PubMed ID: 23320796
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal.
Costa J; Fiorentino F; Caldeira D; Inês M; Lopes Pereira C; Pinheiro L; Vaz-Carneiro A; Borges M; Gouveia M
Rev Port Cardiol; 2015 Dec; 34(12):723-37. PubMed ID: 26616542
[TBL] [Abstract][Full Text] [Related]
37. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
Adcock AK; Lee-Iannotti JK; Aguilar MI; Hoffman-Snyder CR; Wingerchuk DM; Wellik KE; Demaerschalk BM
Neurologist; 2012 Mar; 18(2):102-7. PubMed ID: 22367842
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Kansal AR; Zheng Y; Pokora T; Sorensen SV
Best Pract Res Clin Haematol; 2013 Jun; 26(2):225-37. PubMed ID: 23953910
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
Shah SV; Gage BF
Circulation; 2011 Jun; 123(22):2562-70. PubMed ID: 21606397
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
